It is simple, scalable, and easy to calculate. However, in clinical practice, simplicity often comes at the expense of accuracy, and BMI is failing to meet the standards of modern medicine as it doesn’t account for factors such as body composition, ethnicity, or differences between the sexes.
To improve outcomes in obesity and cardiometabolic disease, we need a broader approach.
BMI alone can’t capture the complexity of metabolic health or adequately guide treatment decisions in a population where risk is driven by factors far beyond weight.
BMI is not designed for modern metabolic care
BMI was originally developed as a population-level statistical tool, not a clinical diagnostic instrument. It does not differentiate between fat and lean mass, does not account for fat distribution, and offers no insight into metabolic function. Two individuals with identical BMIs can have dramatically different risk profiles; one metabolically healthy, the other living with significant insulin resistance, high cholesterol, or hypertension.
When outdated measurements of metabolic health serve as the primary gatekeepers to care eligibility, treatment pathways, and coverage decisions, they introduce blind spots. Patients who would benefit from early intervention may be overlooked, while others may receive care that is not appropriately calibrated to their underlying risk.
Obesity is not simply a condition of excess weight. It is a chronic, relapsing disease with complex physiological, behavioral, and environmental drivers. It is deeply intertwined with cardiovascular, kidney, and metabolic health. A measurement system that fails to reflect this complexity will inevitably fall short.
The need for a multidimensional view of metabolic health
Metabolic health is dynamic. It evolves, influenced by glycemic control, lipid levels, blood pressure, and behavioral patterns, requiring a framework that integrates multiple elements.
Clinicians already think this way in practice by assessing risk using validated tools and laboratory data, and by considering coexisting conditions, medication burden, and behavioral factors that influence outcomes. Yet our measurement systems, and often our benefit designs, lag.
What is needed is a more precise, clinically grounded way to assess metabolic control. One that reflects not only where a patient is today, but also the intensity of care they require to achieve meaningful, sustained improvement.
A more clinically meaningful measurement
To address this gap, Vida developed the Metabolic Control Index (MCI). Unlike population-level statistical tools, the MCI is a composite clinical scoring framework designed to provide holistic care for individuals living with interconnected metabolic conditions.
It moves beyond relying on a single diagnosis code or a static metric like BMI to assess a member’s current level of metabolic control, acuity, and care-intensity needs.
The MCI integrates multiple, clinically validated domains to provide a holistic view of health, including:
- Validated Clinical Assessments: Standardized tools such as the ASCVD 10-Year Risk Estimator, Metabolic Syndrome Severity Test, and mental health screenings (e.g., GAD-7, PHQ-8).
- Objective Clinical Indicators: Key physiological markers like glycemic trends, blood pressure, lipid parameters, and weight trajectory.
- Clinical Complexity: Factors such as coexisting conditions, medication burden, and family history.
- Behavioral Signals: Assessments of dietary patterns, physical activity, and tobacco use.
Critically, the MCI is designed to be data-informed but not data-dependent. This keeps clinical judgment central, allowing the treating clinician to adjust the care pathway and align it with how medicine is actually practiced through a more nuanced and accurate understanding of metabolic health.
From measurement to action
The value of a more sophisticated index like the MCI lies in its ability to inform care, and measurement alone is not the goal.
At Vida, we use the MCI to place individuals into pathways based on their level of metabolic control and clinical complexity. This allows care teams to tailor treatment strategies, ranging from lifestyle and behavioral support to pharmacotherapy, in proportion to risk.
This approach reflects a shift from treating obesity as a uniform condition to managing metabolic health as a spectrum. It acknowledges that progress is more than pounds lost and must also be evaluated by improvements in metabolic control, cardiovascular risk, and overall quality of life.
A patient who achieves modest weight loss but significantly improves their A1C, lowers their blood pressure, and reduces their medication burden has made substantial progress, yet outdated measurement tools don’t accurately reflect that success.
By expanding how we measure metabolic health, we also expand how we define and recognize progress. This is critical for both patient engagement and long-term outcomes.
A path forward
The limitations of BMI are well understood within the medical community, and now is the time to transition toward a better approach that is both clinically rigorous and financially responsible.
As obesity and cardiometabolic disease continue to rise in prevalence and complexity, our measurement frameworks must evolve in parallel. A multidimensional, clinically grounded approach—such as Vida’s Metabolic Control Index (MCI)—offers a clear path forward.
The MCI acts as a clinical governance engine for metabolic health. By precisely stratifying patients based on their true clinical acuity, the MCI ensures that care intensity aligns with need. This reduces unnecessary high-cost interventions for stable members while accelerating timely escalation for those who require physician-led management or medication optimization (e.g., GLP-1s).
This system aligns measurement with medicine. It supports more precise, individualized care based on continuous, real-world data, enabling providers to have a clearer picture of a member’s dynamic status between visits.
Moving beyond BMI is not about discarding a familiar tool, but about building a more complete, clinically meaningful approach to achieving durable health improvements and demonstrating scalable outcomes.
